Clinical Trials Browser

ulixertinib × Clear all

NCT05985954 2026-03-12

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05804227 2026-02-27

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

Phase EARLY_PHASE1 Recruiting

Glioma

NCT03417739 2026-02-25

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Phase 2 Terminated

13 enrolled 9 charts

Uveal Melanoma

NCT03155620 2026-02-10

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2 Active not recruiting

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06411821 2025-12-15

Ulixertinib in People With Histiocytic Neoplasms

Phase 2 Recruiting

Histiocytic Neoplasms

NCT03698994 2025-12-03

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Active not recruiting

20 enrolled 9 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT05221320 2025-09-25

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Phase 2 Terminated

47 enrolled 18 charts

Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms

NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase 1 Recruiting

DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

NCT04145297 2024-11-18

UTAH

Phase 1 Completed

Gastrointestinal

Gastrointestinal Neoplasms

NCT04488003 2024-06-04

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Phase 2 Terminated

104 enrolled 13 charts

Other solid neoplasm

Advanced Solid Tumor

NCT02608229 2021-04-21

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 1 Terminated

18 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02296242 2019-01-29

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Phase 1/2 Completed

53 enrolled 16 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute